Browse the evidence

Increased heart rate was observed across NN1706 treatment cohorts.

Clinicians should monitor heart rate in patients receiving NN1706 treatment.

There is an urgent need to develop effective therapies for diabetes to reduce the risks of serious complications.

Healthcare systems should prioritize the development of new diabetes therapies.

The most common components of metabolic syndrome in the cohort were abdominal obesity and elevated blood pressure.

Understanding common MetS components can guide targeted interventions.

Challenges with GLP-1s include side effects, nutritional deficiencies, and low long-term adherence.

Clinicians should be aware of and manage these challenges when prescribing GLP-1s.

In postmenopausal females with type 2 diabetes, an intensive lifestyle intervention decreased estradiol levels by 15% and bioavailable testosterone by 13% at year 1.

Practitioners should consider the hormonal changes in females when implementing weight loss interventions.

Sleep restriction reduced fat oxidation during high-dose insulin infusion in postmenopausal women.

Practitioners should be aware that sleep restriction may impair fat oxidation in this population.

For 13 dietary risk factors, the best pooled unbiased effect size on disease was identified.

Practitioners can use these effect sizes to inform dietary recommendations.

Low energy availability did not enhance performance when expressed relative to body mass.

Performance assessments should consider body mass to accurately evaluate the effects of energy availability.

In the intervention group, there was statistically significantly higher Part B spending compared to the control group (difference, $513; P = .02).

Practitioners should be aware that while overall spending did not decrease, specific areas like Part B spending increased.

No evidence of a relationship was found between RIR accuracy and biological sex, years of RT experience, or relative bench press strength.

RIR accuracy can be considered independent of these demographic and experiential factors.

GLP-1 receptor agonists were originally developed as glucose lowering agents.

Understanding the original purpose of GLP-1 receptor agonists can inform their use in weight management.

Tirzepatide has similar gastrointestinal adverse reactions and contraindications as traditional GLP-1 receptor agonists.

Clinicians should be aware of the potential for similar side effects when prescribing tirzepatide.

Relevant articles on cardiovascular disease prevention in obesity, atherogenic dyslipidaemia, and chronic kidney disease have been included.

Practitioners should consider the impact of obesity and related conditions on cardiovascular health.

Rapid weight loss induced by semaglutide can lead to noticeable facial volume loss and the appearance of a prematurely aged face, referred to as 'Ozempic face.'

Healthcare providers should be aware of the potential cosmetic implications of semaglutide use for weight loss.

The characteristics of 'Ozempic face' occur in people much younger than what is seen with the natural aging process.

Clinicians should consider age-related factors when assessing patients for semaglutide treatment.

Intranasal delivery of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could overcome the limitations of subcutaneous administration for obesity treatment.

Practitioners should consider intranasal delivery methods for improving patient adherence and reducing side effects.

Innovative approaches for nasal delivery of GLP-1 RAs show promising preclinical results.

Practitioners should consider these innovative approaches to enhance the effectiveness of GLP-1 RA delivery.

The incidence of obesity-related glomerulopathy has increased 10-fold in recent years.

Awareness of obesity-related kidney issues is essential for healthcare providers.

Intentional weight loss can increase health risk in the long-term due to the release of persistent organic pollutants (POPs) from adipose tissue.

Practitioners should consider the potential long-term health risks associated with weight loss due to POP exposure.

Chronic exposure to low levels of POPs is a new risk factor for common metabolic and cardiovascular diseases.

Awareness of POPs as a risk factor can guide health interventions and weight management strategies.

The release of POPs during weight loss may have harmful effects that are opposite to the expected benefits of losing weight.

Weight loss strategies should consider the potential negative impacts of POP release.

There is no strong evidence that there is an optimal ratio of macronutrients for improving glycaemic control or reducing cardiovascular risk.

Practitioners should be cautious in recommending specific macronutrient ratios for diabetes management.

GB participants used fewer glucose-lowering medications at 10 years, but HbA1c, fasting glucose, calculated cardiovascular risk, quality-of-life, and incident diabetes complications did not differ significantly between the groups.

While GB surgery may reduce the need for glucose-lowering medications, it does not significantly improve other health metrics.

Indirect calorimetry is the favored method to assess human energy expenditure and is the only method enabling the assessment of macronutrient oxidation.

Practitioners should consider using indirect calorimetry for accurate assessment of energy expenditure and macronutrient oxidation.